Real world outcomes of momelotinib in myelofibrosis patients with anemia: results from the MOMGEMFIN study - Summary - MDSpire

Real world outcomes of momelotinib in myelofibrosis patients with anemia: results from the MOMGEMFIN study

  • By

  • Lucía Pérez-Lamas

  • Adrián Segura Diaz

  • Regina García Delgado

  • Alberto Álvarez-Larrán

  • María Alicia Senin

  • Elvira Mora

  • María Laura Fox

  • Irene Pastor Galan

  • Gemma Azaceta

  • Sara Garrido Paniagua

  • Raúl Pérez Lopez

  • Diana Margarita Trejos Carvajal

  • Anna Angona

  • Carmen Albo López

  • Pablo Lorente Alegre

  • Miriam Vara

  • Juan Antonio Vera Goñi

  • Dunia De Miguel Llorente

  • Ángeles Fernández Rodríguez

  • Alberto Marín Sanchez

  • Adriana Hernando Megido

  • María Teresa Gómez Casares

  • Ruth Stuckey

  • Gonzalo Carreño-Tarragona

  • Natalia De Las Heras Rodriguez

  • Blanca Xicoy

  • Manuel Pérez Encinas

  • Raquel Mata Serna

  • Lucia Núñez Martin-Buitrago

  • Francisca Ferrer Marín

  • Neus Amer Salas

  • Carolina Guillén Rienda

  • Patricia Velez

  • Laura Lamarca Eraso

  • Sandra Martín

  • Iryna Luts Khoroz

  • Erik De Cabo López

  • Angela Gil

  • Sofía Martín-Consuegra Ramos

  • Fernando Marco De Lucas

  • María José́ Otero Martinez-Fornes

  • María Luisa Martín Mateos

  • Teresa Arquero

  • Elena Cabezudo Pérez

  • Luis Antonio López Gómez

  • Ángela Martínez Hellin

  • Aurelia Tejedor

  • Esther Herrera de Pablo

  • María Isabel Mata Vazquez

  • Inmaculada Castillo Valero

  • María José Fernández

  • Carlos Aguilar

  • Marta Santaliestra

  • Antonio García Menchon

  • Begoña Navas Elorza

  • María Antonia Duran

  • María Pérez Sala

  • Teresa Hernández Santamaría

  • Ma Ángeles Muñoz Jarreño

  • Julio Dávila-Valls

  • Williana Torres Jiménez

  • Joan Alfons Gonzálvez Fernández

  • Hugo Alexander Torres Mantilla

  • Teresa Cobo Rodríguez

  • Aitor Abuin Blanco

  • Francisco Pérez

  • Santiago Osorio Prendes

  • Paola Beneit Villena

  • Raisa Peralta

  • Federico Herrera

  • Eloi Cañamero Giro

  • Reyes Jiménez Bárcenas

  • Mercedes Gasior Kabat

  • Sonia González De Villambrosia

  • Mariana Teresa Tercero-Mora Rodriguez

  • Marina Menéndez Cuevas

  • Beatriz Cuevas Ruiz

  • Marta Fonseca-Santos

  • Sonia Garcés Piquer

  • Rosalía De La Puerta

  • Álvaro Lorenzo Vizcaya

  • Juan Carlos Hernández Boluda

  • Valentín García Gutiérrez

  • April 17, 2025

  • 0 min

Share

Objective:

To evaluate the efficacy and safety of momelotinib in real-world settings for myelofibrosis patients with anemia, specifically focusing on its impact on hemoglobin levels and transfusion dependency.

Key Findings:
  • 154 patients included, median age 73 years; 76.6% had prior JAK inhibitor exposure.
  • At 3 months, 26.9% of transfusion-dependent anemia patients achieved major response; median Hb increased from 7.7 to 8.7 g/dL, indicating significant clinical improvement.
  • In the non-transfusion dependent group, 47.8% achieved major response at 3 months; median Hb increased from 8.9 to 10.2 g/dL.
  • 62.2% of patients with splenomegaly showed spleen size reduction, highlighting the drug's efficacy.
  • 94% of patients had disease-related symptoms at baseline; 92% showed sustained improvement, suggesting a positive impact on quality of life.
Interpretation:

Momelotinib demonstrates promising efficacy in improving hemoglobin levels, reducing transfusion dependency, and alleviating symptoms in myelofibrosis patients with anemia.

Limitations:
  • Retrospective design may introduce bias, potentially affecting the reliability of the findings.
  • Limited follow-up duration (median 5.05 months) restricts long-term efficacy assessment.
  • Small sample size and lack of control group limit the generalizability of the results.
Conclusion:

Momelotinib is effective in treating myelofibrosis patients with anemia, showing significant improvements in hemoglobin levels and symptom relief, which may influence future treatment strategies.

Original Source(s)

Real world outcomes of momelotinib in myelofibrosis patients with anemia: results from the MOMGEMFIN study

  • by Lucía Pérez-Lamas, Adrián Segura Diaz, Regina García Delgado, Alberto Álvarez-Larrán, María Alicia Senin, Elvira Mora, María Laura Fox, Irene Pastor Galan, Gemma Azaceta, Sara Garrido Paniagua, Raúl Pérez Lopez, Diana Margarita Trejos Carvajal, Anna Angona, Carmen Albo López, Pablo Lorente Alegre, Miriam Vara, Juan Antonio Vera Goñi, Dunia De Miguel Llorente, Ángeles Fernández Rodríguez, Alberto Marín Sanchez, Adriana Hernando Megido, María Teresa Gómez Casares, Ruth Stuckey, Gonzalo Carreño-Tarragona, Natalia De Las Heras Rodriguez, Blanca Xicoy, Manuel Pérez Encinas, Raquel Mata Serna, Lucia Núñez Martin-Buitrago, Francisca Ferrer Marín, Neus Amer Salas, Carolina Guillén Rienda, Patricia Velez, Laura Lamarca Eraso, Sandra Martín, Iryna Luts Khoroz, Erik De Cabo López, Angela Gil, Sofía Martín-Consuegra Ramos, Fernando Marco De Lucas, María José́ Otero Martinez-Fornes, María Luisa Martín Mateos, Teresa Arquero, Elena Cabezudo Pérez, Luis Antonio López Gómez, Ángela Martínez Hellin, Aurelia Tejedor, Esther Herrera de Pablo, María Isabel Mata Vazquez, Inmaculada Castillo Valero, María José Fernández, Carlos Aguilar, Marta Santaliestra, Antonio García Menchon, Begoña Navas Elorza, María Antonia Duran, María Pérez Sala, Teresa Hernández Santamaría, Ma Ángeles Muñoz Jarreño, Julio Dávila-Valls, Williana Torres Jiménez, Joan Alfons Gonzálvez Fernández, Hugo Alexander Torres Mantilla, Teresa Cobo Rodríguez, Aitor Abuin Blanco, Francisco Pérez, Santiago Osorio Prendes, Paola Beneit Villena, Raisa Peralta, Federico Herrera, Eloi Cañamero Giro, Reyes Jiménez Bárcenas, Mercedes Gasior Kabat, Sonia González De Villambrosia, Mariana Teresa Tercero-Mora Rodriguez, Marina Menéndez Cuevas, Beatriz Cuevas Ruiz, Marta Fonseca-Santos, Sonia Garcés Piquer, Rosalía De La Puerta, Álvaro Lorenzo Vizcaya, Juan Carlos Hernández Boluda, Valentín García Gutiérrez

  • April 17, 2025

Related Content

The 51st Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians Award Winners (O001-O007)

  • November 5, 2025

Evaluation of gecacitinib vs hydroxyurea in patients with intermediate-2 or high-risk myelofibrosis: final analysis results from a randomized phase 3 study

Assessment of Clinical Complications and Treatment Approaches in Non-Transfusion-Dependent α- and β-Thalassemia Patients Compared to Matched Controls: A Retrospective Analysis Utilizing Administrative Claims Data in the United States